News & Updates

With the follow-up extended for an additional year, the RATIONALE-309 trial demonstrates a continued PFS advantage following the addition of tislelizumab to chemo for the 1L treatment of recurrent/metastatic NPC, as shown in the 3-year follow-up results presented at ESMO Asia 2024

Oral semaglutide, when used in routine clinical practice, appears effective in managing type 2 diabetes (T2D) even in “very elderly” populations.

In the AIRFLO study, treatment with ziresovir – a potent, selective, orally administered RSV F protein inhibitor – leads to a greater resolution of signs and symptoms of bronchiolitis in hospitalized infants and young children with respiratory syncytial virus (RSV) infection.

In individuals experiencing dyspnoea after sustaining a SARS-CoV-2 infection, physiotherapy, particularly pulmonary rehabilitation, may be beneficial in mitigating respiratory symptoms, according to the results of a systematic review and meta-analysis.

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with cancer cachexia and elevated levels of growth differentiation factor-15 (GDF-15), GDF-15 inhibition with ponsegromab led to a significant increase in body weight and overall activity level and reduction in cachexia symptoms, a phase II study suggests.

Targeting interleukin-31 signalling with nemolizumab appears to produce substantial improvements in core signs and symptoms of prurigo nodularis (PN), as shown in the phase III OLYMPIA 1 trial.